Breaking News Instant updates and real-time market news.

SBBP

Strongbridge Biopharma

$3.55 /

-0.03 (-0.84%)

08:19
09/08/20
09/08
08:19
09/08/20
08:19

Strongbridge Biopharma sees FY20 KEVEYIS revenue $28M-$29M

Strongbridge reports unaudited KEVEYIS July and August 2020 combined revenue of approximately $5.5 million, resulting in 2020 year-to-date unaudited revenue of approximately $20 million, which is a 39 percent increase over revenue of $14.4 million for the January through August period in 2019. The Company increased KEVEYIS full-year revenue guidance for 2020 to $28 million to $29 million from $22 million to $26 million.

  • 17

    Nov

SBBP Strongbridge Biopharma
$3.55 /

-0.03 (-0.84%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI

TODAY'S FREE FLY STORIES

Periodicals
China has reasons to like Tiktok's Trump-approved deal, WSJ reports » 15:58
09/20/20
09/20
15:58
09/20/20
15:58
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

A White House-approved…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

Periodicals
Tiktok deal facing questions over security, ownership, WSJ reports » 15:58
09/20/20
09/20
15:58
09/20/20
15:58
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

President Trump agreed in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

Conference/Events
UBS consumer goods analyst to hold an analyst/industry conference call » 15:22
09/20/20
09/20
15:22
09/20/20
15:22
NKE

Nike

$114.63 /

-1.73 (-1.49%)

Consumer Analyst Sole,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

09/18/20 Needham
Nike price target raised to $132 from $113 at Needham
09/18/20 Morgan Stanley
Nike price target raised to $142 from $121 at Morgan Stanley
09/18/20 Raymond James
Nike price target raised to $121 from $115 at Raymond James
09/18/20 Barclays
Nike price target raised to $132 from $118 at Barclays
NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

Conference/Events
UBS healthcare analysts to hold an analyst/industry conference call » 15:19
09/20/20
09/20
15:19
09/20/20
15:19

Healthcare Analysts Mayo,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Express participates in a conference call with Cowen » 15:10
09/20/20
09/20
15:10
09/20/20
15:10
EXPR

Express

$0.91 /

-0.0604 (-6.23%)

Cowen Retail Analyst Chen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EXPR Express
$0.91 /

-0.0604 (-6.23%)

EXPR Express
$0.91 /

-0.0604 (-6.23%)

01/27/20 B. Riley FBR
Express price target raised to $4.50 from $4 at B. Riley FBR
01/22/20 Wedbush
Wedbush 'incrementally positive' on Express following strategic update
EXPR Express
$0.91 /

-0.0604 (-6.23%)

EXPR Express
$0.91 /

-0.0604 (-6.23%)

Conference/Events
Cardiff Oncology to hold a KOL conference call » 15:05
09/20/20
09/20
15:05
09/20/20
15:05
CRDF

Cardiff Oncology

$8.69 /

+0.58 (+7.15%)

Management holds a Key…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

09/18/20 Maxim
Cardiff Oncology price target raised to $14 from $6 at Maxim
CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

Conference/Events
Sarepta to hold a conference call » 14:56
09/20/20
09/20
14:56
09/20/20
14:56
SRPT

Sarepta

$144.60 /

+0.62 (+0.43%)

Management discuss…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

09/15/20 Citi
Sarepta price target raised to $190 from $177 at Citi
09/10/20 Piper Sandler
Sarepta filing for SRP-9001 could still meet expectations, says Piper Sandler
09/10/20 Mizuho
Sarepta potential study delay 'largely immaterial,' says Mizuho
09/10/20 Goldman Sachs
Sarepta Phase 3 timelines 'could remain intact,' says Goldman Sachs
SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

Hot Stocks
Analysis shows AstraZeneca Tagrisso demonstrated improvement in CNS DFS » 14:52
09/20/20
09/20
14:52
09/20/20
14:52
AZN

AstraZeneca

$56.47 /

+0.53 (+0.95%)

Results from a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
09/09/20 SVB Leerink
AstraZeneca COVID vaccine hold may cause ripple, says SVB Leerink
AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

Conference/Events
Merck to hold an investor briefing » 14:52
09/20/20
09/20
14:52
09/20/20
14:52
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Management provides an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Hot Stocks
Bristol-Myers, Exelixis announce results from Phase 3 CheckMate -9ER trial » 14:45
09/20/20
09/20
14:45
09/20/20
14:45
EXEL

Exelixis

$26.78 /

-0.16 (-0.59%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Bristol Myers Squibb…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
08/03/20 Credit Suisse
Ipsen price target raised to EUR 86 from EUR 69 at Credit Suisse
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

Hot Stocks
Ipsen announces results from Phase III CheckMate -9ER trial » 14:37
09/20/20
09/20
14:37
09/20/20
14:37
EXEL

Exelixis

$26.78 /

-0.16 (-0.59%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Ipsen (IPSEY) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
08/03/20 Credit Suisse
Ipsen price target raised to EUR 86 from EUR 69 at Credit Suisse
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

Hot Stocks
Genentech presents new data from multiple Phase III studies of Tecentriq in TNBC » 14:21
09/20/20
09/20
14:21
09/20/20
14:21
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Merck announces findings from Phase 3 EORTC1325/KEYNOTE-054 trial » 14:13
09/20/20
09/20
14:13
09/20/20
14:13
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Merck, known as MSD…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Hot Stocks
Zai Lab announced results from NORA study » 14:08
09/20/20
09/20
14:08
09/20/20
14:08
ZLAB

Zai Lab

$79.26 /

-1.29 (-1.60%)

Zai Lab has announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ZLAB Zai Lab
$79.26 /

-1.29 (-1.60%)

ZLAB Zai Lab
$79.26 /

-1.29 (-1.60%)

08/14/20 Guggenheim
Zai Lab price target raised to $111 from $105 at Guggenheim
07/09/20 Roth Capital
Turning Point agreement with Zai Lab favorable, says Roth Capital
07/08/20 Guggenheim
Zai Lab price target raised to $105 from $75 at Guggenheim
07/07/20 SVB Leerink
Zai Lab price target raised to $93 from $79 at SVB Leerink
ZLAB Zai Lab
$79.26 /

-1.29 (-1.60%)

  • 23
    Jan
On The Fly
Opening Day: Snowflake shares double in biggest software IPO ever » 08:16
09/20/20
09/20
08:16
09/20/20
08:16
CRM

Salesforce

$242.67 /

-1.855 (-0.76%)

, BRK.A

Berkshire Hathaway

$327,677.00 /

+1255.99 (+0.38%)

, BRK.B

Berkshire Hathaway

$218.05 /

+0.06 (+0.03%)

, SNOW

Snowflake

$237.60 /

+10.6 (+4.67%)

, FROG

JFrog

$65.00 /

-1.13 (-1.71%)

, SUMO

Sumo Logic

$25.21 /

-1.44 (-5.40%)

, SPLK

Splunk

$175.04 /

-2.51 (-1.41%)

, ESTC

Elastic

$103.17 /

+0.74 (+0.72%)

, U

Unity Software

$68.25 /

+ (+0.00%)

, BNL

Broadstone Net Lease

$16.67 /

+0.41 (+2.52%)

, PTVE

Pactiv Evergreen

$11.75 /

+0.68 (+6.14%)

, AMWL

Amwell

$22.96 /

-0.72 (-3.04%)

, DYN

Dyne Therapeutics

$22.80 /

-0.81 (-3.43%)

, STEP

Stepstone Group

$24.99 /

+0.09 (+0.36%)

, MTCR

Metracrine

$10.03 /

-0.32 (-3.09%)

, OM

Outset Medical

$60.22 /

-2.38 (-3.80%)

, ATHA

Athira Pharma

$17.50 /

+ (+0.00%)

, RTP

Reinvent Technology Partners

$0.00 /

+ (+0.00%)

, SBG

Sandbridge Acquisition

$0.00 /

+ (+0.00%)

, AIRB

Airbnb

$0.00 /

+ (+0.00%)

, IH

iHuman

$0.00 /

+ (+0.00%)

, ORPH

Orphazyme

$0.00 /

+ (+0.00%)

, GRAY

Graybug Vision

$0.00 /

+ (+0.00%)

, GOOG

Alphabet

$1,459.36 /

-36.47 (-2.44%)

, GOOGL

Alphabet Class A

$1,451.09 /

-37.51 (-2.52%)

, GLNG

Golar LNG

$13.93 /

+1.03 (+7.98%)

, HYGO

Hygo Energy

$0.00 /

+ (+0.00%)

, IKT

Inhibikase Therapeutics

$0.00 /

+ (+0.00%)

, TSHA

Taysha Gene Therapies

$0.00 /

+ (+0.00%)

Shares of Snowflake, a…

ShowHide Related Items >><<
SPLK Splunk
$175.04 /

-2.51 (-1.41%)

SNOW Snowflake
$237.60 /

+10.6 (+4.67%)

GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

GLNG Golar LNG
$13.93 /

+1.03 (+7.98%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

09/18/20 Baird
Salesforce benefitting from pandemic ecommerce burst, says Baird
08/26/20 Morgan Stanley
Salesforce price target raised to $275 from $195 at Morgan Stanley
08/26/20 JPMorgan
Salesforce price target raised to $250 from $200 at JPMorgan
08/26/20 Monness Crespi
Salesforce price target raised to $275 from $195 at Monness Crespi
BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

SNOW Snowflake
$237.60 /

+10.6 (+4.67%)

FROG JFrog
$65.00 /

-1.13 (-1.71%)

SUMO Sumo Logic
$25.21 /

-1.44 (-5.40%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

08/31/20 Argus
Splunk price target raised to $260 from $215 at Argus
08/27/20
Fly Intel: Top five analyst upgrades
08/27/20 Needham
Splunk price target raised to $250 from $192 at Needham
08/27/20 DA Davidson
Splunk price target raised to $240 from $190 at DA Davidson
ESTC Elastic
$103.17 /

+0.74 (+0.72%)

08/27/20 FBN Securities
Elastic price target raised to $125 from $95 at FBN Securities
08/27/20 Stifel
Elastic price target raised to $125 from $84 at Stifel
08/27/20 Monness Crespi
Elastic price target raised to $142 from $100 at Monness Crespi
08/27/20 DA Davidson
Elastic price target raised to $130 from $100 at DA Davidson
U Unity Software
$68.25 /

+ (+0.00%)

BNL Broadstone Net Lease
$16.67 /

+0.41 (+2.52%)

PTVE Pactiv Evergreen
$11.75 /

+0.68 (+6.14%)

AMWL Amwell
$22.96 /

-0.72 (-3.04%)

DYN Dyne Therapeutics
$22.80 /

-0.81 (-3.43%)

STEP Stepstone Group
$24.99 /

+0.09 (+0.36%)

MTCR Metracrine
$10.03 /

-0.32 (-3.09%)

OM Outset Medical
$60.22 /

-2.38 (-3.80%)

ATHA Athira Pharma
$17.50 /

+ (+0.00%)

RTP Reinvent Technology Partners
$0.00 /

+ (+0.00%)

SBG Sandbridge Acquisition
$0.00 /

+ (+0.00%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

IH iHuman
$0.00 /

+ (+0.00%)

ORPH Orphazyme
$0.00 /

+ (+0.00%)

GRAY Graybug Vision
$0.00 /

+ (+0.00%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

09/18/20 Morgan Stanley
AES Corp. price target raised to $23.50 from $19 at Morgan Stanley
09/14/20 KeyBanc
Alphabet initiated with an Overweight at KeyBanc
08/25/20 UBS
Alphabet price target raised to $1,970 from $1,600 at UBS
08/12/20 JPMorgan
Broadcom likely co-designed Google's next-gen AI chip, says JPMorgan
GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

09/15/20
Fly Intel: Top five analyst initiations
09/14/20 KeyBanc
Alphabet initiated with an Overweight at KeyBanc
GLNG Golar LNG
$13.93 /

+1.03 (+7.98%)

09/01/20 DNB Markets
Golar LNG upgraded to Buy from Hold at DNB Markets
05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
04/08/20 B. Riley FBR
Golar LNG price target lowered to $13 from $21 at B. Riley FBR
03/09/20 DNB Markets
Golar LNG downgraded to Hold from Buy at DNB Markets
HYGO Hygo Energy
$0.00 /

+ (+0.00%)

IKT Inhibikase Therapeutics
$0.00 /

+ (+0.00%)

TSHA Taysha Gene Therapies
$0.00 /

+ (+0.00%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

GLNG Golar LNG
$13.93 /

+1.03 (+7.98%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

  • 24
    Sep
  • 25
    Sep
  • 18
    Sep
  • 17
    Sep
  • 15
    Sep
  • 18
    Sep
  • 16
    Sep
  • 16
    Sep
  • 17
    Sep
  • 17
    Sep
  • 16
    Sep
  • 17
    Sep
  • 17
    Sep
  • 16
    Sep
U Unity Software
$68.25 /

+ (+0.00%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

SUMO Sumo Logic
$25.21 /

-1.44 (-5.40%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

SNOW Snowflake
$237.60 /

+10.6 (+4.67%)

IKT Inhibikase Therapeutics
$0.00 /

+ (+0.00%)

GOOG Alphabet
$1,459.36 /

-36.47 (-2.44%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

BRK.B Berkshire Hathaway
$218.05 /

+0.06 (+0.03%)

BRK.A Berkshire Hathaway
$327,677.00 /

+1255.99 (+0.38%)

BNL Broadstone Net Lease
$16.67 /

+0.41 (+2.52%)

AIRB Airbnb
$0.00 /

+ (+0.00%)

SPLK Splunk
$175.04 /

-2.51 (-1.41%)

GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

ESTC Elastic
$103.17 /

+0.74 (+0.72%)

CRM Salesforce
$242.67 /

-1.855 (-0.76%)

GOOGL Alphabet Class A
$1,451.09 /

-37.51 (-2.52%)

Periodicals
Nikola outsourced batteries on truck prototype, FT reports » 07:46
09/20/20
09/20
07:46
09/20/20
07:46
GM

General Motors

$31.50 /

-0.42 (-1.32%)

, NKLA

Nikola

$34.25 /

+0.37 (+1.09%)

Nikola (NKLA) is relying…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

09/17/20 Roth Capital
Roth raises Workhorse target to $33 after Lordstown's 'compelling' analyst day
09/17/20 Deutsche Bank
GM news 'potentially disruptive' to powertrain suppliers, says Deutsche Bank
09/14/20 JPMorgan
Core criticism of Nikola short report 'misconceived,' says JPMorgan
09/10/20 Barclays
General Motors price target raised to $39 from $34 at Barclays
NKLA Nikola
$34.25 /

+0.37 (+1.09%)

09/16/20 JPMorgan
JPMorgan says talks with Nikola CFO 'reassuring'
09/14/20 Wedbush
Nikola remains a 'prove me' stock, says Wedbush
09/09/20 RBC Capital
Nikola price target raised to $49 from $46 at RBC Capital
NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

NKLA Nikola
$34.25 /

+0.37 (+1.09%)

GM General Motors
$31.50 /

-0.42 (-1.32%)

Periodicals
Trump supports deal to allow TikTok to continue operating in U.S., Reuters says » 18:35
09/19/20
09/19
18:35
09/19/20
18:35
WMT

Walmart

$135.30 /

-1.39 (-1.02%)

, ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

President Donald Trump…

President Donald Trump said he supports a deal that will allow TikTok to continue to operate in the United States, after threatening to ban the Chinese-owned app in August, Reuters' Alexandra Alper and David Shepardson report. He told reporters at the White House he backs the deal with Oracle (ORCL) and Walmart (WMT) that would see the creation of a new company that will assume TikTok's U.S. operations, the authors note. Trump said the new TikTok company will be "totally controlled by Oracle and Walmart.... All of the control is Oracle and Walmart." Reference Link

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Hot Stocks
Immunomedics says Phase 2 'positive' in metastatic urothelial cancer » 14:25
09/19/20
09/19
14:25
09/19/20
14:25
IMMU

Immunomedics

$85.50 /

+0.19 (+0.22%)

Immunomedics announced…

Immunomedics announced "positive" results from cohort 1 of cisplatin-eligible patients in the pivotal Phase 2 TROPHY U-01 study of Trodelvy in metastatic urothelial cancer. Results confirm the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC who progressed on both platinum-based chemotherapy and checkpoint inhibitors, the company said. The median progression-free survival was 5.4 months and median overall survival was 10.5 months. "Given that only about 10 percent of patients with mUC who have cancer progression after platinum-based and CPI therapy are expected to respond to single-agent chemotherapy with approximately two to three months of median progression-free survival, today's compelling results with sacituzumab govitecan offer patients and families new hope," commented Yohann Loriot, MD, PhD, Institut de Cancerologie Gustave Roussy, Villejuif, France.

ShowHide Related Items >><<
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/17/20 Piper Sandler
Novocure price target raised to $125 from $89 at Piper Sandler
09/15/20
Fly Intel: Top analyst downgrades
09/15/20 Guggenheim
Immunomedics downgraded to Neutral from Buy at Guggenheim
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

  • 29
    Apr
  • 05
    Dec
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

Hot Stocks
Immunomedics' Trodelvy extended overall survival in breast cancer study » 14:22
09/19/20
09/19
14:22
09/19/20
14:22
IMMU

Immunomedics

$85.50 /

+0.19 (+0.22%)

Immunomedics announced…

Immunomedics announced that results from the confirmatory Phase 3 ASCENT study showed that Trodelvy "significantly extended" overall survival and improved overall response rate and clinical benefit rate, compared to treatment of choice standard single-agent chemotherapy in brain metastases-negative patients with mTNBC who had previously received at least two prior therapies for metastatic disease. Despite having received a median of four prior anticancer regimens, patients treated with Trodelvy in the ASCENT study showed a statistically significant and clinically meaningful improvement in OS with a median of 12.1 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.48, the company said. Trodelvy also demonstrated a statistically significant improvement in ORR and CBR compared to chemotherapy, Immunomedics added. Ten complete responses were observed in the Trodelvy arm compared with two in the control group. As of data cutoff on March 11, 2020, 15 patients continued to receive Trodelvy treatment while no patient remained on study in the TPC control arm. "We believe these remarkable results should facilitate the establishment of Trodelvy as a new standard of care in patients with third-line mTNBC," said Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics. "We are working very collaboratively with FDA under the RTOR program to submit a supplemental Biologics License Application to have Trodelvy's label expanded to include these confirmatory new data. Additionally, we plan to submit a Marketing Authorization Application to the European Medicines Agency in the first half of 2021 in order to make this important new treatment available to mTNBC patients in Europe."

ShowHide Related Items >><<
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/17/20 Piper Sandler
Novocure price target raised to $125 from $89 at Piper Sandler
09/15/20
Fly Intel: Top analyst downgrades
09/15/20 Guggenheim
Immunomedics downgraded to Neutral from Buy at Guggenheim
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

  • 29
    Apr
  • 05
    Dec
IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

IMMU Immunomedics
$85.50 /

+0.19 (+0.22%)

Periodicals
CoreLogic battle appears headed to shareholder vote, Barron's says » 10:18
09/19/20
09/19
10:18
09/19/20
10:18
CNNE

Cannae Holdings

$36.18 /

-1.27 (-3.39%)

, CLGX

CoreLogic

$67.32 /

-0.12 (-0.18%)

One of the…

One of the more-confrontational activist battles this year is almost sure to come down to a shareholder vote in November, Carleton English writes in this week's edition of Barron's. Earlier in the week, CoreLogic (CLGX) rejected the second buyout bid by activist investor Senator Investment Group and strategic holding company Cannae Holdings (CNNE), claiming the $66-per-share offer "significantly undervalue(d)" the property data and analytics company, the author notes, adding that admittedly, the duo only increased their initial offer by $1 a share as a "gesture of good faith." They had hoped to restart talks and start a formal due-diligence process to determine if a higher bid is warranted, the report points out. With both sides at a seeming impasse, it's increasingly looking like CoreLogic shareholders will have the final say at the company's special meeting on Nov. 17 in which Senator and Cannae put up a majority slate of director nominees to facilitate a sale process. Reference Link

ShowHide Related Items >><<
CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

06/26/20 Truist
CoreLogic upgraded to Buy from Hold at SunTrust
05/14/20 Stephens
Cannae Holdings price target raised to $43 from $40 at Stephens
11/20/19 Stephens
Stephens says 'don't worry' about new CEO at Cannae Holdings
CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

07/24/20
Fly Intel: Top five analyst downgrades
07/24/20 Stephens
Stephens sees limited further upside for CoreLogic shares, cuts to Equal Weight
07/24/20 Stephens
CoreLogic downgraded to Equal Weight from Overweight at Stephens
07/24/20 Compass Point
CoreLogic downgraded to Neutral from Buy at Compass Point
CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

  • 11
    Jun
  • 04
    Dec
CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

CNNE Cannae Holdings
$36.18 /

-1.27 (-3.39%)

CLGX CoreLogic
$67.32 /

-0.12 (-0.18%)

Periodicals
Albertsons a Buy as stock looks cheap, Barron's says » 10:11
09/19/20
09/19
10:11
09/19/20
10:11
ACI

Albertsons

$13.07 /

-0.21 (-1.58%)

With Americans eating…

With Americans eating more meals at home, supermarkets are among the few traditional retailers to thrive, and Albertsons, the nation's fourth-largest grocer, is no exception, Andrew Bary writes in this week's edition of Barron's. Since the pandemic began in March, the owner of the Safeway and Acme supermarket chains has had sales growth of more than 20% and ample profits. However, the company went public in late June at $16 a share, and the stock has since fallen to around $13, the author notes, adding that now is the time "to bag these marked-down shares." Reference Link

ShowHide Related Items >><<
ACI Albertsons
$13.07 /

-0.21 (-1.58%)

ACI Albertsons
$13.07 /

-0.21 (-1.58%)

09/14/20 Morgan Stanley
Kimco Realty upgraded to Overweight on free cash flow at Morgan Stanley
08/11/20
Kimco Realty increased to Overweight from Neutral at Piper Sandler
08/06/20 Credit Suisse
Albertsons assumed with an Outperform at Credit Suisse
07/30/20 MKM Partners
Albertsons initiated with a Neutral at MKM Partners
  • 26
    Jun
ACI Albertsons
$13.07 /

-0.21 (-1.58%)

ACI Albertsons
$13.07 /

-0.21 (-1.58%)

ACI Albertsons
$13.07 /

-0.21 (-1.58%)

Periodicals
Nvidia's deal for Arm risky, 'quite smart,' Barron's says » 10:06
09/19/20
09/19
10:06
09/19/20
10:06
TSM

TSMC

$80.21 /

-1.69 (-2.06%)

, INTC

Intel

$49.89 /

-0.44 (-0.87%)

, NVDA

Nvidia

$487.24 /

-11.3 (-2.27%)

Nvidia (NVDA) became the…

Nvidia (NVDA) became the largest U.S. chip maker by market value in July, passing industry titan Intel (INTC), but by most measures, Nvidia remains a niche player, Max Cherney writes in this week's edition of Barron's. For Nvidia to grow into its value, the company has to do something big, and CEO Jensen Huang may have found the answer with his $40B deal for Arm Holdings, the author notes. If there ever was a way to challenge Intel's dominance, Huang may have cracked the code, with a combination of Nvidia's leading graphics processors, Arm's central-processing-unit chips, and its longstanding partnership with TSMC (TSM), which fabricates many of the world's most advanced chips, the report adds. Reference Link

ShowHide Related Items >><<
TSM TSMC
$80.21 /

-1.69 (-2.06%)

NVDA Nvidia
$487.24 /

-11.3 (-2.27%)

INTC Intel
$49.89 /

-0.44 (-0.87%)

TSM TSMC
$80.21 /

-1.69 (-2.06%)

08/28/20 New Street
TSMC initiated with a Buy at New Street
08/24/20 Northland
Northland downgrades AMD to Market Perform on potential Intel, data center risks
07/29/20 Bernstein
ASML downgraded to Market Perform on customer slowdown at Bernstein
07/27/20 Lynx
Might be prudent to take profits on TSMC, wait for pullback, Lynx says
INTC Intel
$49.89 /

-0.44 (-0.87%)

09/18/20 Northland
Combined Nvidia-ARM a long-term risk for AMD, Intel and Vicor, says Northland
09/15/20 Craig-Hallum
Nvidia price target raised to $500 from $480 at Craig-Hallum
09/14/20 RBC Capital
RBC Capital sees ARM Holdings deal as positive for Nvidia, negative for Intel
09/08/20 Standpoint Research
Intel upgraded to Buy from Hold at Standpoint Research
NVDA Nvidia
$487.24 /

-11.3 (-2.27%)

09/15/20 Needham
Nvidia price target raised to $700 from $600 at Needham
09/15/20 Oppenheimer
Nvidia's acquisition of ARM strengthens AI hand, says Oppenheimer
TSM TSMC
$80.21 /

-1.69 (-2.06%)

NVDA Nvidia
$487.24 /

-11.3 (-2.27%)

INTC Intel
$49.89 /

-0.44 (-0.87%)

TSM TSMC
$80.21 /

-1.69 (-2.06%)

NVDA Nvidia
$487.24 /

-11.3 (-2.27%)

INTC Intel
$49.89 /

-0.44 (-0.87%)

TSM TSMC
$80.21 /

-1.69 (-2.06%)

NVDA Nvidia
$487.24 /

-11.3 (-2.27%)

INTC Intel
$49.89 /

-0.44 (-0.87%)

TSM TSMC
$80.21 /

-1.69 (-2.06%)

NVDA Nvidia
$487.24 /

-11.3 (-2.27%)

INTC Intel
$49.89 /

-0.44 (-0.87%)

Periodicals
PayPal, Square among best performers as COVID makes cash history, Barron's says » 10:03
09/19/20
09/19
10:03
09/19/20
10:03
SQ

Square

$145.07 /

-0.565 (-0.39%)

, PYPL

PayPal

$176.01 /

+0.25 (+0.14%)

Cash usage was already at…

Cash usage was already at an all-time low, and COVID-19 has just hastened the decline, with Americans at first stuck at home and now still wary of the close proximity require for the physical exchange of bills, Daren Fonda writes in this week's edition of Barron's. Meanwhile, digital payment stocks like PayPal Holdings (PYPL) and Square (SQ) have been some of the best performers in 2020, pushing their valuations to extremes. The elevated prices could pressure the stocks in the near term, keeping further gains muted, but for long-term investors, there's still time to jump in, the author notes. Reference Link

ShowHide Related Items >><<
SQ Square
$145.07 /

-0.565 (-0.39%)

PYPL PayPal
$176.01 /

+0.25 (+0.14%)

SQ Square
$145.07 /

-0.565 (-0.39%)

09/16/20 Mizuho
Square lending product could add 10% in gross profit, says Mizuho
08/27/20 Mizuho
Mizuho starts Square with Buy rating, $225 price target
08/26/20 Mizuho
Square initiated with a Buy at Mizuho
08/20/20 Deutsche Bank
Square price target raised to $180 from $140 at Deutsche Bank
PYPL PayPal
$176.01 /

+0.25 (+0.14%)

09/15/20 Baird
PayPal's Venmo remains favored digital wallet by 'wide margin,' says Baird
08/31/20 Keefe Bruyette
KBW boosts PayPal target to $238, names best idea for second half
08/28/20 Truist
MasterCard price target raised to $415 from $375 at Truist
08/27/20 Mizuho
Mizuho starts PayPal with Buy rating, $285 price target
SQ Square
$145.07 /

-0.565 (-0.39%)

PYPL PayPal
$176.01 /

+0.25 (+0.14%)

SQ Square
$145.07 /

-0.565 (-0.39%)

PYPL PayPal
$176.01 /

+0.25 (+0.14%)

SQ Square
$145.07 /

-0.565 (-0.39%)

PYPL PayPal
$176.01 /

+0.25 (+0.14%)

SQ Square
$145.07 /

-0.565 (-0.39%)

PYPL PayPal
$176.01 /

+0.25 (+0.14%)

On The Fly
Week in review: How Trump's policies moved stocks » 09:23
09/19/20
09/19
09:23
09/19/20
09:23
AZN

AstraZeneca

$56.47 /

+0.53 (+0.95%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, LLY

Eli Lilly

$154.23 /

+1.74 (+1.14%)

, GSK

GlaxoSmithKline

$39.26 /

-0.2 (-0.51%)

, JNJ

Johnson & Johnson

$149.12 /

+2.03 (+1.38%)

, MRK

Merck

$85.82 /

+0.17 (+0.20%)

, NVS

Novartis

$90.92 /

+0.07 (+0.08%)

, PFE

Pfizer

$36.61 /

-0.2 (-0.54%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SNY

Sanofi

$52.42 /

+0.34 (+0.65%)

, ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

, DK

Delek US

$11.89 /

-0.2 (-1.65%)

, HFC

HollyFrontier

$22.00 /

-0.26 (-1.17%)

, MPC

Marathon Petroleum

$32.26 /

+0.14 (+0.44%)

, PSX

Phillips 66

$59.83 /

-0.51 (-0.85%)

, TSO

Tesoro

$0.00 /

+ (+0.00%)

, VLO

Valero

$48.77 /

-0.23 (-0.47%)

, WNR

Western Refining

$0.00 /

+ (+0.00%)

, FB

Facebook

$252.53 /

-2.49 (-0.98%)

Catch up on the top…

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

VLO Valero
$48.77 /

-0.23 (-0.47%)

SNY Sanofi
$52.42 /

+0.34 (+0.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PSX Phillips 66
$59.83 /

-0.51 (-0.85%)

PFE Pfizer
$36.61 /

-0.2 (-0.54%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

NVS Novartis
$90.92 /

+0.07 (+0.08%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MPC Marathon Petroleum
$32.26 /

+0.14 (+0.44%)

LLY Eli Lilly
$154.23 /

+1.74 (+1.14%)

JNJ Johnson & Johnson
$149.12 /

+2.03 (+1.38%)

HFC HollyFrontier
$22.00 /

-0.26 (-1.17%)

GSK GlaxoSmithKline
$39.26 /

-0.2 (-0.51%)

FB Facebook
$252.53 /

-2.49 (-0.98%)

DK Delek US
$11.89 /

-0.2 (-1.65%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
09/09/20 SVB Leerink
AstraZeneca COVID vaccine hold may cause ripple, says SVB Leerink
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
LLY Eli Lilly
$154.23 /

+1.74 (+1.14%)

09/16/20 Canaccord
Eli Lilly COVID-19 data bodes well for Regeneron, says Canaccord
09/16/20 Goldman Sachs
Eli Lilly COVID-19 antibody data 'encouraging,' says Goldman Sachs
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
09/03/20
Fly Intel: Top five analyst upgrades
GSK GlaxoSmithKline
$39.26 /

-0.2 (-0.51%)

09/18/20 Societe Generale
GlaxoSmithKline price target raised to 2,350 GBp at Societe Generale
09/08/20 JPMorgan
GlaxoSmithKline price target lowered to 1,650 GBp from 1,700 GBp at JPMorgan
09/01/20 AlphaValue
GlaxoSmithKline upgraded to Buy from Add at AlphaValue
09/01/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,700 GBp from 1,725 GBp at Morgan Stanley
JNJ Johnson & Johnson
$149.12 /

+2.03 (+1.38%)

09/01/20 Morgan Stanley
Catalent has potential upside from COVID vaccine, says Morgan Stanley
08/25/20 H.C. Wainwright
Momenta downgraded to Neutral from Buy at H.C. Wainwright
08/24/20 Raymond James
Momenta initiated with a Market Perform at Raymond James
08/24/20 Raymond James
Argenx initiated with an Outperform at Raymond James
MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
NVS Novartis
$90.92 /

+0.07 (+0.08%)

09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
09/01/20 Morgan Stanley
Novartis upgraded to Overweight from Equal Weight at Morgan Stanley
08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
08/18/20 Raymond James
Teva could pay damages nearing $1B in DOJ FCA action, says Raymond James
PFE Pfizer
$36.61 /

-0.2 (-0.54%)

09/16/20 Baird
uniQure weakness a buying opportunity, says Baird
09/15/20 Citi
Sarepta price target raised to $190 from $177 at Citi
09/09/20 JMP Securities
Trillium Therapeutics price target raised to $14 from $10 at JMP Securities
RHHBY Roche
$0.00 /

+ (+0.00%)

09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
SNY Sanofi
$52.42 /

+0.34 (+0.65%)

09/14/20 Roth Capital
Immunic has 'significant' opportunity in RRMS, says Roth Capital
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/19/20 Stifel
Principia Biopharma downgraded to Hold from Buy at Stifel
08/18/20 SVB Leerink
Principia Biopharma downgraded to Market Perform at SVB Leerink
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
DK Delek US
$11.89 /

-0.2 (-1.65%)

09/11/20 JPMorgan
Delek US price target lowered to $13 from $19 at JPMorgan
08/06/20 Scotiabank
Scotiabank downgrades Delek to Underperform on near-term negative catalysts
08/06/20 Scotiabank
Delek US downgraded to Underperform from Sector Perform at Scotiabank
07/09/20 Tudor Pickering
Delek US upgraded to Hold from Sell at Tudor Pickering
HFC HollyFrontier
$22.00 /

-0.26 (-1.17%)

09/11/20 JPMorgan
HollyFrontier price target lowered to $28 from $34 at JPMorgan
08/07/20 Goldman Sachs
HollyFrontier upgraded to Neutral from Sell at Goldman Sachs
07/22/20 Mizuho
HollyFrontier downgraded to Neutral on higher spending at Mizuho
07/22/20 Mizuho
HollyFrontier downgraded to Neutral from Buy at Mizuho
MPC Marathon Petroleum
$32.26 /

+0.14 (+0.44%)

09/11/20 JPMorgan
Marathon Petroleum price target lowered to $37 from $44 at JPMorgan
08/12/20 Cowen
Marathon Petroleum upgraded to Outperform from Market Perform at Cowen
08/04/20 Tudor Pickering
Marathon Petroleum downgraded to Sell from Buy at Tudor Pickering
08/03/20 Morgan Stanley
Marathon sale of Speedway for $21B a 'positive outcome,' says Morgan Stanley
PSX Phillips 66
$59.83 /

-0.51 (-0.85%)

09/11/20 JPMorgan
Phillips 66 price target lowered to $75 from $79 at JPMorgan
08/25/20 Raymond James
Phillips 66 price target lowered to $75 from $80 at Raymond James
07/22/20 Wells Fargo
Phillips 66 Partners downgraded to Equal Weight from Overweight at Wells Fargo
07/20/20 Jefferies
Phillips 66 upgraded to Buy at Jefferies following pullback
TSO Tesoro
$0.00 /

+ (+0.00%)

VLO Valero
$48.77 /

-0.23 (-0.47%)

09/11/20 JPMorgan
Valero price target lowered to $59 from $68 at JPMorgan
08/25/20 Raymond James
Valero price target lowered to $63 from $69 at Raymond James
07/20/20 Jefferies
Valero upgraded to Buy at Jefferies following pullback
07/20/20 Jefferies
Valero upgraded to Buy from Hold at Jefferies
WNR Western Refining
$0.00 /

+ (+0.00%)

FB Facebook
$252.53 /

-2.49 (-0.98%)

09/18/20 Morgan Stanley
Facebook price target raised to $295 from $285 at Morgan Stanley
09/15/20
Fly Intel: Top five analyst initiations
09/14/20 KeyBanc
Facebook initiated with an Overweight at KeyBanc
09/14/20 KeyBanc
Facebook initiated with an Overweight at KeyBanc
WMT Walmart
$135.30 /

-1.39 (-1.02%)

VLO Valero
$48.77 /

-0.23 (-0.47%)

SNY Sanofi
$52.42 /

+0.34 (+0.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PSX Phillips 66
$59.83 /

-0.51 (-0.85%)

PFE Pfizer
$36.61 /

-0.2 (-0.54%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

NVS Novartis
$90.92 /

+0.07 (+0.08%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MPC Marathon Petroleum
$32.26 /

+0.14 (+0.44%)

LLY Eli Lilly
$154.23 /

+1.74 (+1.14%)

JNJ Johnson & Johnson
$149.12 /

+2.03 (+1.38%)

HFC HollyFrontier
$22.00 /

-0.26 (-1.17%)

GSK GlaxoSmithKline
$39.26 /

-0.2 (-0.51%)

FB Facebook
$252.53 /

-2.49 (-0.98%)

DK Delek US
$11.89 /

-0.2 (-1.65%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

SNY Sanofi
$52.42 /

+0.34 (+0.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PSX Phillips 66
$59.83 /

-0.51 (-0.85%)

PFE Pfizer
$36.61 /

-0.2 (-0.54%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

NVS Novartis
$90.92 /

+0.07 (+0.08%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MPC Marathon Petroleum
$32.26 /

+0.14 (+0.44%)

LLY Eli Lilly
$154.23 /

+1.74 (+1.14%)

JNJ Johnson & Johnson
$149.12 /

+2.03 (+1.38%)

HFC HollyFrontier
$22.00 /

-0.26 (-1.17%)

GSK GlaxoSmithKline
$39.26 /

-0.2 (-0.51%)

FB Facebook
$252.53 /

-2.49 (-0.98%)

DK Delek US
$11.89 /

-0.2 (-1.65%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

VLO Valero
$48.77 /

-0.23 (-0.47%)

SNY Sanofi
$52.42 /

+0.34 (+0.65%)

PFE Pfizer
$36.61 /

-0.2 (-0.54%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

NVS Novartis
$90.92 /

+0.07 (+0.08%)

MPC Marathon Petroleum
$32.26 /

+0.14 (+0.44%)

LLY Eli Lilly
$154.23 /

+1.74 (+1.14%)

JNJ Johnson & Johnson
$149.12 /

+2.03 (+1.38%)

GSK GlaxoSmithKline
$39.26 /

-0.2 (-0.51%)

FB Facebook
$252.53 /

-2.49 (-0.98%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

VLO Valero
$48.77 /

-0.23 (-0.47%)

SNY Sanofi
$52.42 /

+0.34 (+0.65%)

PSX Phillips 66
$59.83 /

-0.51 (-0.85%)

PFE Pfizer
$36.61 /

-0.2 (-0.54%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MPC Marathon Petroleum
$32.26 /

+0.14 (+0.44%)

LLY Eli Lilly
$154.23 /

+1.74 (+1.14%)

JNJ Johnson & Johnson
$149.12 /

+2.03 (+1.38%)

GSK GlaxoSmithKline
$39.26 /

-0.2 (-0.51%)

FB Facebook
$252.53 /

-2.49 (-0.98%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

Periodicals
Roku, Comcast reach deal to carry Peacock on Roku, Verge reports » 18:06
09/18/20
09/18
18:06
09/18/20
18:06
ROKU

Roku

$160.52 /

-4.11 (-2.50%)

, CMCSA

Comcast

$45.26 /

-0.35 (-0.77%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

Comcast (CMCSA) and Roku…

Comcast (CMCSA) and Roku (ROKU) have reached a deal months after NBCUniversal's Peacock streaming service rolled out, The Verge's Julia Alexander reports, noting that Peacock will be available to stream on Roku devices in the coming weeks. "We are pleased to have reached an agreement with Comcast that will bring Peacock to Roku customers and maintains access to NBCU's TV Everywhere apps," a Roku spokesperson said. "We look forward to offering these new options to consumers under an expanded, mutually beneficial relationship between our companies that includes adding NBC content to The Roku Channel and a meaningful partnership around advertising." Reference Link

ShowHide Related Items >><<
ROKU Roku
$160.52 /

-4.11 (-2.50%)

CMCSK Comcast
$0.00 /

+ (+0.00%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

ROKU Roku
$160.52 /

-4.11 (-2.50%)

09/18/20 Rosenblatt
Rosenblatt would be buyer on any Roku weakness amid latest Comcast 'tiff'
09/15/20
Fly Intel: Top five analyst initiations
09/14/20 KeyBanc
Roku initiated with an Overweight at KeyBanc
09/14/20 KeyBanc
Roku initiated with an Overweight at KeyBanc
CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
08/24/20 BWS Financial
Xperi initiated with a Buy at BWS Financial
08/03/20 Deutsche Bank
Comcast price target raised to $53 from $47 at Deutsche Bank
CMCSK Comcast
$0.00 /

+ (+0.00%)

07/01/20
Fly Intel: Top five analyst upgrades
04/28/20 Wells Fargo
SeaWorld price target lowered to $16 from $36 at Wells Fargo
04/17/20 Oppenheimer
Comcast downgraded to Perform from Outperform at Oppenheimer
ROKU Roku
$160.52 /

-4.11 (-2.50%)

CMCSK Comcast
$0.00 /

+ (+0.00%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

  • 17
    Mar
ROKU Roku
$160.52 /

-4.11 (-2.50%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

ROKU Roku
$160.52 /

-4.11 (-2.50%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

ROKU Roku
$160.52 /

-4.11 (-2.50%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.